The Data
/
Stocks
/ AORT
Equity · Healthcare
$21.77
−0.55% vs prior close
Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 16, 2026
1D
1M
3M
1Y
5Y
All
Price · Chart
63 sessions
$30.0
$20.0
21 Jul
16 Oct
The line runs $24.98 on 21 July through $21.77 on 16 October, on a scale from $20.0 to $30.0. Days the market did not trade hold the previous close, flat.
Interactive AORT price chart by TradingView (requires JavaScript).
Market cap
$1.1B
52-week range
$20 – $48
Avg volume
31.6K
as of Oct 16, 2026
About Artivion, Inc.
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. Its main product families include aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. The company operates through two segments: Medical Devices, which covers sales of its primary products, and Preservation Services, which provides preservation of implantable human tissues. Artivion’s customers are primarily cardiac and vascular surgeons.
Company
Exchange
NYSE
Sector
Healthcare
Class
Equity
Insiders Form 4
Filings 5 sets
AORT insider trades
SEC Form 4 · last 90 days · newest reported trade 10 Sep 2026
Open-market buys
0
Open-market sells
7
Net sold
$2.60M
Non-trade filings
0
Date
Insider
Type
Shares
Value
10 Sep 2026
GREEN ANDREW M
SVP, Regulatory and Quality
Sell
11,480
$287K
03 Sep 2026
GREEN ANDREW M
SVP, Regulatory and Quality
Sell
1,493
$39K
02 Sep 2026
GREEN ANDREW M
SVP, Regulatory and Quality
Sell
6,510
$177K
19 Aug 2026
Mackin James P
President & CEO
Sell
70,000
$2.03M
14 Aug 2026
Berry Lance A
EVP, COO, CFO & Treasurer
Sell
715
$20K
14 Aug 2026
GREEN ANDREW M
SVP, Regulatory and Quality
Sell
616
$18K
12 Aug 2026
Holloway Jean F
SVP, General Counsel
Sell
977
$28K
AORT reported financials
SEC EDGAR XBRL
SEC EDGAR
AORT reported revenue of $441.3M for the fiscal year ended 31 Dec 2025. Net income over the same period was $9.8M.
Figure
Reported
Period
Revenue
$441.3M
31 Dec 2025
fiscal year
Net income
$9.8M
31 Dec 2025
fiscal year
Diluted EPS
$0.21
31 Dec 2025
fiscal year
Total assets
$1.1B
30 Jun 2026
at period end
Total equity
$445.6M
30 Jun 2026
at period end
AORT earnings
SEC EDGAR
Date
Period
EPS
Revenue
30 Jun 2026
Q2 2026
−$0.28
—
31 Mar 2026
Q1 2026
$0.03
—
31 Dec 2025
FY 2025
$0.21
—
30 Sep 2025
Q3 2025
$0.13
—
30 Jun 2025
Q2 2025
$0.03
—
31 Mar 2025
Q1 2025
−$0.01
—
31 Dec 2024
FY 2024
−$0.32
—
30 Sep 2024
Q3 2024
−$0.05
—
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
6 of the 45 institutional funds we track reported a AORT position for the quarter ended 30 Jun 2026 — a combined $47.6M; the latest of those filings landed 02 Sep 2026.
AORT fails-to-deliver
SEC CNS data
SEC
On 25 Sep 2026, 2,442 shares of AORT failed to deliver (about $56K).
Settlement date
Shares failed
Notional
% of shares out
25 Sep 2026
2,442
$56K
0.005%
11 Sep 2026
1,570
$39K
0.003%
The most recent congressional trade disclosed in AORT is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 20 Aug 2026.
Date
Member
Type
Amount
20 Aug 2026
filed 10 Sep 2026
Gilbert Ray Cisneros, Jr.
house · Democrat–CA
Purchase
$1K–$15K
09 Oct 2025
filed 18 Nov 2025
Gilbert Ray Cisneros, Jr.
house · Democrat–CA
Sale
$1K–$15K
14 Jul 2023
filed 21 Aug 2023
Josh Gottheimer
house · Democrat–NJ
Purchase
$1K–$15K
13 Jun 2023
filed 11 Jul 2023
Josh Gottheimer
house · Democrat–NJ
Sale
$1K–$15K
Sources
Finazon prior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source TradingView the price chart widget, drawn by TradingView from their own data SEC EDGAR SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026 SEC EDGAR SEC EDGAR 13F filings SEC SEC fails-to-deliver (CNS) data House disclosures U.S. House of Representatives financial disclosures SEC EDGAR Valuation computed from SEC EDGAR filings